Can Pralsetinib be used to treat children?

As to whether pralsetinib (Pralsetinib) can be used in pediatric patients, there is currently insufficient data to support its widespread use in the pediatric population. Platinib is a targeted therapy drug targeting RET gene fusion. It is mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer patients. Most clinical trials and approved indications have focused on adult patients, with limited research data on pediatric patients, so use in children without the guidance of a professional physician is not recommended.

Some early-stage studies are evaluating platinib's potential in childhood cancers, particularly in certain rare childhood cancers associated with RETfusions. However, most of these studies are in phase I/II, with small sample sizes, and safety and effectiveness have not been fully verified. Currently, no major global drug regulatory agency (such as FDA or EMA) has clearly approved platinib for the treatment of children, so there are still risks and uncertainties in its use.

If platinib is considered for use in pediatric patients, the decision must be made under the guidance of a specialist oncologist, combined with genetic testing results and specific tumor types. In actual clinical operations, treatment options that have been proven to be safe and effective for children are generally given priority. Only when there are no other alternative drugs and the benefits are assessed to outweigh the risks, it is possible to try to use treatment options that are not yet widely recognized, such as platinib.

To sum up, platinib is not currently a drug routinely recommended for the treatment of childhood tumors. For pediatric cancer patients with RETfusion, they should actively seek multidisciplinary consultation and advice from authoritative cancer centers, and pay close attention to relevant clinical trial trends to obtain safer and more effective treatment paths.

Reference materials:https://www.drugs.com/